Obeticholic Acid

Hepatic Decompensation and Failure in Incorrectly Dosed PBC Patients with Child-Puch Class B or C or Decompensated Cirrhosis

  • In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended 
  • The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event

Patient counseling

Communications

Medical guidelines

Package inserts

Keywords: Ocaliva
Updated: March 2018